Cart
sales@molnova.com
ZXH-3-26 B
CAS No. 2243076-67-5
ZXH-3-26 B( —— )
Catalog No. M33536 CAS No. 2243076-67-5
ZXH-3-26 is a PROTAC composed of a Cereblon ligand, an E3 ubiquitin ligase, and a BRD4 ligand that can be used to study cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 350 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameZXH-3-26 B
-
NoteResearch use only, not for human use.
-
Brief DescriptionZXH-3-26 is a PROTAC composed of a Cereblon ligand, an E3 ubiquitin ligase, and a BRD4 ligand that can be used to study cancer.
-
DescriptionZXH-3-26 is a PROTAC connected by ligands for Cereblon and BRD4 with a DC50/5h of 5 nM. The DC50/5h refers to half-maximal degradation after 5 hours of treatment of ~ 5 nM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorPROTACs
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2243076-67-5
-
Formula Weight785.27
-
Molecular FormulaC38H37ClN8O7S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 200 mg/mL (254.69 mM; Ultrasonic )
-
SMILESCC=1C2=C(N3C([C@H](CC(OC)=O)N=C2C4=CC=C(Cl)C=C4)=NN=C3C)SC1C(NCCCCCNC5=C6C(C(=O)N(C6=O)C7C(=O)NC(=O)CC7)=CC=C5)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Nowak RP, et al. Plasticity in binding confers selectivity in ligand-induced protein degradation. Nat Chem Biol. 2018 Jul;14(7):706-714.?
molnova catalog
related products
-
BI-9321 trihydrochlo...
BI-9321 trihydrochloride (BI9321 trihydrochloride) is a selective and potent NSD3-PWWP1 antagonist that downregulates Myc messenger RNA expression and reduces proliferation in MOLM-13 cells.
-
PF-03814735
PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.
-
MYLS22
MYLS22 is a first-in-class and selective optic atrophy 1 (OPA1) inhibitor.
